Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Effect of cysteinyl leukotriene receptor antagonist on airway wall remodeling Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in the airway remodeling induced by chronic airway inflammation in guinea pigs Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2009; 34: 1444-1451 Year: 2009
Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Leukotriene receptor antagonist versus corticotherapy on airways responsiveness in ovalbumin sensitized rats Source: Eur Respir J 2003; 22: Suppl. 45, 478s Year: 2003
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
A role of prostaglandin D2 receptor, CRTH2, on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010